Pictet Asset Management
DAWN

Pictet Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Pictet Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$279K Sell
13,034
-2,977,767
-100% -$42M ﹤0.01% 1750
2025
Q4 		$27.9M Buy
2,990,801
+617,668
+26% +$5.16M 0.03% 446
2025
Q3 		$16.7M Sell
2,373,133
-1,349,599
-36% -$9.29M 0.02% 559
2025
Q2 		$24.2M Buy
3,722,732
+87,152
+2% +$600K 0.02% 465
2025
Q1 		$28.8M Buy
3,635,580
+145,516
+4% +$1.57M 0.03% 411
2024
Q4 		$44.2M Buy
3,490,064
+507,398
+17% +$7.06M 0.05% 325
2024
Q3 		$41.5M Buy
2,982,666
+131,092
+5% +$1.87M 0.05% 331
2024
Q2 		$39.3M Buy
2,851,574
+476,437
+20% +$6.97M 0.05% 325
2024
Q1 		$39.2M Sell
2,375,137
-196,431
-8% -$2.94M 0.04% 359
2023
Q4 		$37.5M Buy
2,571,568
+1,971,529
+329% +$23.9M 0.04% 356
2023
Q3 		$7.36M Buy
+600,039
New +$7.83M 0.01% 681

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Pictet Asset Management's DAWN Position: Q1 2026 in Review

Pictet Asset Management reduced its Day One Biopharmaceuticals (DAWN) stake by 100% in Q1 2026, selling an estimated $42M and leaving 13,034 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Pictet Asset Management first reported a position in DAWN in Q3 2023 and has held it in 11 quarters since. The position peaked at $44.2M in Q4 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Pictet Asset Management held 13,034 shares of Day One Biopharmaceuticals worth $279K as of Q1 2026.
  • Pictet Asset Management sold 2,977,767 Day One Biopharmaceuticals shares in Q1 2026, an estimated $42M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1750 holding.
  • Pictet Asset Management first reported a position in Day One Biopharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Day One Biopharmaceuticals position peaked at $44.2M in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.